CRISPR therapy setback: Intellia pauses Phase 3 ATTR trials as patient develops serious liver reaction to nex-z

Intellia Therapeutics has paused dosing in its Phase 3 MAGNITUDE trials after a patient experienced severe liver toxicity, as ...
BioPharma Dive

FDA places formal hold on two Intellia CRISPR trials

Two days after Intellia voluntarily paused dosing due to safety concerns, the regulator stepped in with an official hold that ...

Intellia stock tumbles after pausing gene therapy trials on safety concerns

Intellia Therapeutics (NASDAQ:NTLA) stock tumbled 50% Monday after the company announced it has temporarily paused patient dosing and screening for its Phase 3 clinical trials of nex-z due to a ...

Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z)

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the company has ...
BioSpace

Intellia Pauses Phase III ATTR Trials for CRISPR Gene Therapy After Life-Threatening Liver Toxicity

Intellia earlier this year reported a similar grade 4 liver enzyme elevation associated with the gene therapy nexiguran ...
NPR

Customized CRISPR treatments could help people with rare genetic disorders

The gene-editing technique known as CRISPR is promising to revolutionize medicine. Some researchers are trying to help make it available for people with very rare genetic disorders. A gene-editing ...
InvestorsHub on MSN

Intellia stock plunges after halting gene therapy trials over safety issue

Intellia Therapeutics (NASDAQ:NTLA) shares plummeted 50% on Monday after the company announced a temporary halt to patient dosing and screening in its Phase 3 trials of nex-z, citing a serious ...

Intellia pauses gene therapy trials after patient suffers liver injury, shares slide

Intellia Therapeutics has temporarily stopped dosing and patient screening in two late-stage studies of its gene therapy after a participant developed serious liver injury, the company said on Monday, ...